Phase 4Status unknown

A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

A Randomized,Active-controlled,Open-label Clinical Trial to Evaluate the Effect of GLP-1 Receptor Agonist (Exenatide Injection) in Combination With Metformin Therapy Compared to Premixed Insulin (BIAsp30) in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

Sponsor
The First Hospital of Jilin University (Academic or other)
Enrollment
200 planned
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide; BIAsp30; Metformin
Ages
adults, older adults
Registry
NCT03018665

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese

Primary outcomes

  • Rate of Inducing Diabetes Remission
  • Change of Rate of Maintaining Diabetes Remission
  • Time of Maintaining Diabetes Remission

History

  1. Primary completion

  2. Started

  3. Registered